Fig. 4From: The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysisForest plots of the meta-analysis on the effects of antiangiogenic drugs on overall survival (OS). Compared with the control group, angiogenesis inhibitor group can significantly improve OSBack to article page